SALUTENSIN
Clinical safety rating
cautionComprehensive clinical and safety monograph for SALUTENSIN (SALUTENSIN).
Salutensin is a combination of two antihypertensive agents: hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption; and reserpine, a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from presynaptic nerve terminals by irreversibly blocking vesicular monoamine transporter (VMAT), leading to decreased peripheral vasoconstriction and heart rate.
| Metabolism | Hydroflumethiazide: not extensively metabolized, mainly excreted unchanged in urine. Reserpine: extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces. |
| Excretion | Primarily renal (65-75% as unchanged drug); biliary/fecal (20-30%) with enterohepatic recirculation; minor metabolism via CYP3A4 to inactive metabolites. |
| Half-life | Terminal elimination half-life: 18-24 hours (mean 20 h); clinically, requires 5-7 days to reach steady state; prolonged in renal impairment (CrCl <30 mL/min: up to 40 h) and in elderly. |
| Protein binding | 98% bound to albumin and α1-acid glycoprotein; binding is concentration-independent; altered in hypoalbuminemia. |
| Volume of Distribution | 0.15-0.25 L/kg (approx. 10-18 L in 70 kg adult); indicates moderate tissue distribution; Vd increased in hypertension (0.3 L/kg) and decreased in heart failure. |
| Bioavailability | Oral: 85-95% due to extensive absorption and minimal first-pass metabolism; food delays absorption but does not reduce extent; IV and IM: 100%. |
| Onset of Action | Oral: 1-2 hours; IV: 15-30 minutes; IM: 30-60 minutes. |
| Duration of Action | Oral: 24-36 hours (allows once-daily dosing); IV: 18-24 hours; antihypertensive effect persists for up to 48 hours after last dose. |
| Molecular Weight | 480.42 |
Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if GFR <30 mL/min. If GFR 30-50 mL/min, reduce dose to half tablet daily and monitor potassium; avoid if potassium >5.5 mmol/L. |
| Liver impairment | Contraindicated in Child-Pugh class C. In class A or B, use with caution; start at half tablet daily and monitor hepatic function. |
| Pediatric use | Not recommended for children under 18 years due to lack of safety data. |
| Geriatric use | Start at half tablet daily (25 mg spironolactone + 2.5 mg bendroflumethiazide). Monitor renal function, electrolytes, and blood pressure closely. Avoid if creatinine clearance <30 mL/min. |
| 1st trimester | Contraindicated due to risk of fetal renal dysfunction, oligohydramnios, and skull ossification defects. |
| 2nd trimester | Contraindicated; may cause fetal hypotension, decreased placental perfusion, and oligohydramnios. |
| 3rd trimester | Contraindicated; risk of neonatal hypotension, hyperkalemia, and renal failure. |
Clinical note
Comprehensive clinical and safety monograph for SALUTENSIN (SALUTENSIN).
| Placental transfer | Crosses the placenta; detected in fetal plasma at concentrations approximately 10-20% of maternal levels. |
| Breastfeeding | Excreted into human milk in low concentrations; however, due to potential for adverse effects in the infant (e.g., hypotension, electrolyte disturbances), caution is advised. Consider alternative agents. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Limited human data; based on animal studies, possible increased risk of congenital anomalies including cardiovascular and renal defects. Second and third trimesters: Risk of fetal hypotension, decreased placental perfusion, oligohydramnios, and neonatal renal dysfunction or failure. Avoid use in pregnancy unless no alternative. |
| Fetal Monitoring | Monitor maternal blood pressure and renal function regularly. Fetal monitoring includes ultrasound for growth, amniotic fluid volume, and biophysical profile. Neonatal monitoring for hypotension and renal function after delivery. |
| Fertility Effects | No human data; animal studies suggest possible reversible impairment of spermatogenesis and decreased libido. Potential for menstrual irregularities. |
■ FDA Black Box Warning
Reserpine may cause mental depression. Therapy should be discontinued at the first sign of depression (e.g., despondency, early morning insomnia, loss of appetite, impotence). Depressive reactions are more common in patients with a history of depression.
| Serious Effects |
Hypersensitivity to spironolactone or any componentAnuriaAcute renal insufficiencySignificant renal impairment (eGFR <30 mL/min/1.73 m2)HyperkalemiaAddison's diseaseConcomitant use with eplerenone or other potassium-sparing diuretics
| Precautions | Electrolyte imbalance (hypokalemia, hyponatremia), hypotension, drowsiness/sedation, depression risk, exacerbation of peptic ulcer or ulcerative colitis, use caution in renal/hepatic impairment, and avoid abrupt discontinuation (reserpine may cause withdrawal syndrome). |
| Food/Dietary | Avoid high-sodium foods as they may reduce antihypertensive effect. Limit alcohol intake due to additive blood pressure lowering and dizziness risk. Ensure adequate potassium intake (e.g., bananas, oranges) unless contraindicated by renal function. |
| Clinical Pearls | SALUTENSIN is a combination of hydrochlorothiazide and reserpine. Monitor for hypokalemia and hyperuricemia due to thiazide; reserpine may cause nasal congestion and depression. Avoid in patients with history of depression or peptic ulcer. Use with caution in renal impairment (CrCl <30 mL/min). |
| Patient Advice | Take this medication exactly as prescribed, usually once daily in the morning to avoid nocturia. · Avoid sudden discontinuation; consult your doctor before stopping. · Report symptoms of depression, unusual mood changes, or nasal congestion to your healthcare provider. · This drug may cause dizziness or drowsiness; avoid driving until you know how it affects you. · Monitor for signs of low potassium (muscle cramps, weakness, irregular heartbeat) or high uric acid (joint pain, swelling). |
Loading safety data…